Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

TriMix-DC (ex-vivo autologous dendritic cells vaccine)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

eTheRNA immunotherapies

Drug class:

CD70 inhibitor, CD40 agonist, TLR4 antagonist

Related drugs:

‹

›

TPSAB1 expression	Melanoma	TPSAB1 expression	Melanoma	ex-vivo autologous dendritic cells vaccine Sensitive: C3 – Early Trials ex-vivo autologous dendritic cells vaccine Sensitive : C3	ex-vivo autologous dendritic cells vaccine Sensitive: C3 – Early Trials ex-vivo autologous dendritic cells vaccine Sensitive : C3
CD9 expression	Melanoma	CD9 expression	Melanoma	ex-vivo autologous dendritic cells vaccine Sensitive: C3 – Early Trials ex-vivo autologous dendritic cells vaccine Sensitive : C3	ex-vivo autologous dendritic cells vaccine Sensitive: C3 – Early Trials ex-vivo autologous dendritic cells vaccine Sensitive : C3
CSF2 expression	Melanoma	CSF2 expression	Melanoma	ex-vivo autologous dendritic cells vaccine Sensitive: C3 – Early Trials ex-vivo autologous dendritic cells vaccine Sensitive : C3	ex-vivo autologous dendritic cells vaccine Sensitive: C3 – Early Trials ex-vivo autologous dendritic cells vaccine Sensitive : C3
STAT2 expression	Melanoma	STAT2 expression	Melanoma	ex-vivo autologous dendritic cells vaccine Sensitive: C3 – Early Trials ex-vivo autologous dendritic cells vaccine Sensitive : C3	ex-vivo autologous dendritic cells vaccine Sensitive: C3 – Early Trials ex-vivo autologous dendritic cells vaccine Sensitive : C3